Video

Dr. Aggarwal on ADT Intensification in Biochemically Relapsed Prostate Cancer

Author(s):

Rahul Aggarwal, MD

In Partnership With:

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.

Rahul Aggarwal, MD, developmental therapeutics specialist, genitourinary oncologist, the University of California Health (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses the rationale for investigating androgen deprivation therapy (ADT) intensification in biochemically relapsed prostate cancer.

The phase 3 PRESTO study (NCT03009981) evaluated ADT alone vs ADT plus apalutamide (Erleada) vs ADT plus apalutamide, abiraterone acetate (Zytiga), and prednisone in men with biochemically recurrent prostate cancer and a prostate specific antigen (PSA) doubling time less than 9 months following radical prostatectomy.

Investigators evaluated intensified therapy on the backbone of ADT over a 52-week period in an effort to suppress PSA and enable longer treatment-free intervals, Aggarwal explains.

The top line interim analysis results for the primary end point of PSA progression-free survival (PFS) were presented at the 2022 ESMO Congress, Aggarwal continues. Patients treated in the 2 experimental arms featuring ADT plus apalutamide and ADT plus apalutamide, abiraterone, and prednisone experienced improved PSA PFS compared with patients who received ADT alone, Aggarwal concludes.

Related Videos
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Related Content
Philip Sutera, MD, of Johns Hopkins University School of Medicine
May 30th 2024

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

James A. Knight II, MD
May 28th 2024

Broadening Differentials in Brain-Metastatic Prostate Cancer Broadens Diagnostic Horizons

Hyunseok (Hyu) Kang, MD, MPH, FACP, associate professor, medical oncologist, the University of California, San Francisco Health
February 29th 2024

Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice

stock.adobe.com
May 24th 2024

Prostate Cancer Study: More Health Benefits from Plant-Based Diet

Timothy Yap, MBBS, PhD, FRCP
May 21st 2024

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors